Subclinical disease activity in systemic lupus erythematosus: Immunoinflammatory markers do not normalize in clinical remission

被引:0
|
作者
Wais, T
Fierz, W
Stoll, T
Villiger, PM
机构
[1] Univ Hosp Bern, Dept Rheumatol & Clin Allergol, CH-3010 Bern, Switzerland
[2] Kantonsspital, Inst Clin Immunol & Microbiol, St Gallen, Switzerland
[3] AarReha Schinznach, Schinznach, Switzerland
关键词
cytokines; cytokine antagonists; disease activity; systemic lupus erythematosus; BILAG; adhesion molecules;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To correlate various laboratory measures in systemic lupus erythematosus (SLE) with the British Isles Lupus Assessment Group (BILAG) disease activity index, to search for organ-specific laboratory patterns and to compare with a control population. Methods. A cohort of 57 Caucasian outpatients fulfilling the American College of Rheumatology criteria for SLE and a control population of 17 patients admitted for coronarography were examined. Disease activity was assessed with BILAG index. Plasma samples were investigated for sCD44, interleukin 6 (IL-6), IL-10, IL-12, tumor necrosis factor-alpha (TNF-alpha), soluble TNF receptor-55 (sTNFR-55), sTNFR-75, IL-1-receptor antagonist, soluble intercellular adhesion molecule (sICAM), soluble vascular cell adhesion molecule (sVCAM), E-selectin, and neopterin as well as for C3, C4, dsDNA, and other conventional indicators. Results. Thirty-nine patients had inactive disease (total BILAG score less than or equal to 5), 18 patients had active SLE. Surprisingly, except for C-reactive protein (p < 0.001), no statistically significant difference of the laboratory indicators was found between patients with active and those with inactive SLE. However, there was a significant difference between SLE patients and controls for sTNFR-75 (p < 0.008). We found significant correlations between laboratory markers and some BILAG organ system scores, such as between IL-1ra and the musculoskeletal score (p < 0.003) and between sTNFR-55/sTNFR-75 and renal BILAG (p < 0.001, p < 0.004, respectively). Significant nonparametric correlations were revealed between C3 and C4 (p < 0.0001), and between sTNFR-75 and dsDNA, neopterin, sVCAM, sICAM and sTNFR-55 concentrations (p < 0.0001 for all), and between sTNFR-75 and IL-1ra (p < 0.006). Conclusion. Patients with SLE in clinical remission show ongoing systemic immunoinflammatory activity measured with a variety of cytokines, adhesion molecules, and other inflammatory markers. This indicates that laboratory measures may provide qualitatively different additional information to validated disease activity indexes such as the BILAG. Different laboratory markers correlate with disease activity in different organ systems. This suggests differences in pathogenic mechanisms in SLE depending on the organ system involved.
引用
收藏
页码:2133 / 2139
页数:7
相关论文
共 50 条
  • [1] Subclinical disease activity in SLE: Immuno-inflammatory markers do not normalize in full clinical remission.
    Wais, T
    Stoll, T
    Kauer, Y
    Villiger, PM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S249 - S249
  • [2] Remission or low disease activity as a target in systemic lupus erythematosus
    Francisco Ugarte-Gil, Manuel
    Wojdyla, Daniel
    Pons-Estel, Guillermo J.
    Pons-Estel, Bernardo A.
    Alarcon, Graciela S.
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (01)
  • [3] Clinical Utility of Selected Disease Activity Markers in Patients with Systemic Lupus Erythematosus
    P. Horák
    V. Ščudla
    Z. Heřmanová
    Z. Pospíšil
    L. Faltýnek
    M. Budíková
    L. Kusá
    Clinical Rheumatology, 2001, 20 : 337 - 344
  • [4] Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus
    Horák, P
    Scudla, V
    Hermanová, Z
    Pospísil, Z
    Faltynek, L
    Budíkovà, M
    Kusà, L
    CLINICAL RHEUMATOLOGY, 2001, 20 (05) : 337 - 344
  • [5] Neurotrophic factors in systemic lupus erythematosus: markers of disease activity
    Dias, A. F. M. P.
    Lanna, C. C. D.
    Teixeira, A. L.
    Ferreira, G. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (06) : 1451 - 1452
  • [6] PREDICTORS OF LOW DISEASE ACTIVITY AND CLINICAL REMISSION FOLLOWING BELIMUMAB TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Parodis, Ioannis
    Johansson, Petter
    Gomez, Alvaro
    Soukka, Sofia
    Emamikia, Sharzad
    Chatzidionysiou, Katerina
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 761 - 761
  • [7] Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus
    Tselios, Konstantinos
    Gladman, Dafna D.
    Touma, Zahi
    Su, Jiandong
    Anderson, Nicole
    Urowitz, Murray B.
    ARTHRITIS CARE & RESEARCH, 2019, 71 (06) : 822 - 828
  • [8] Triglycerides are markers of disease activity in systemic lupus erythematosus.
    Svenungsson, EK
    Fei, GZ
    Gunnarsson, I
    Lundberg, IE
    Grondal, G
    Klareskog, L
    Frostegard, J
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S214 - S214
  • [9] Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
    Parodis, Ioannis
    Johansson, Petter
    Gomez, Alvaro
    Soukka, Sofia
    Emamikia, Sharzad
    Chatzidionysiou, Katerina
    RHEUMATOLOGY, 2019, 58 (12) : 2170 - 2176
  • [10] SEROLOGICAL AND CLINICAL REMISSION IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    HELLER, CA
    SCHUR, PH
    JOURNAL OF RHEUMATOLOGY, 1985, 12 (05) : 916 - 918